# Latigo Biotherapeutics Inc. (LTGO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $23.04, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Latigo Biotherapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Free-cash-flow yield: -6.4%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 47.1%**. 47.1% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.

## Financial health
- **Current ratio: 4.00** (quick 4.00). Current assets cover the next year's liabilities 4.00 times.

## Dividends
- **Dividend: none**. Latigo Biotherapeutics Inc. does not currently pay a dividend, but it returned -9.8% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (4 analysts). 4 analysts cover Latigo Biotherapeutics Inc.; the consensus is strong_buy, with an average price target of $52.25 (+127% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -11.1%** (33.8% above the low). Trading 11% below its 52-week high.
- **RSI (14-day): 65**. An RSI of 65 is neutral.

Live score and charts: https://foliofundamentals.com/analyzer?s=LTGO · Page: https://foliofundamentals.com/stocks/ltgo

Not investment advice.